Ask AI
ProCE Banner Series

Targeting BCMA in Early Relapsed/Refractory Myeloma: What Oncology Pharmacists Need to Know Now and in the Near Future

This 1-hour interactive live webinar will provide expert perspectives on the role and utility of BCMA-targeted agents in patients with early relapsed/refractory MM, including evidence-based rationale supporting the use of these agents and optimal management of the associated adverse events to maximize treatment outcomes.

  ACPE-P
Who Should Attend

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with relapsed/refractory multiple myeloma. 

All Events

Targeting BCMA in Early Relapsed/Refractory Myeloma: What Oncology Pharmacists Need to Know Now and in the Near Future

Upcoming Events

April

30

2026

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

May

27

2026

6:00 PM - 7:00 PM Eastern Time (ET)

Virtual

Topics

Multiple Myeloma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence to optimize the use of BCMA-targeted agents in patients with relapsed/refractory multiple myeloma.

Target Audience
This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with relapsed/refractory multiple myeloma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain the rationale for targeting BCMA to improve outcomes in patients with early R/R MM

  • Summarize recent updates on BCMA-targeted therapies for R/R MM in treatment discussions with physicians and patients.

  • Employ evidence-based strategies to monitor and manage ocular toxicity associated with BCMA-targeted antibody–drug conjugates for early R/R MM in collaboration with the multidisciplinary care team

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-002-L01-P  has been assigned to this live application-based activity (initial release date 4/30/2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles. 

Acknowledgement

Provided by

Provided by ProCE, LLC

ProCE, LLC

Supporters

Supported by an educational grant from GSK.

GSK

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191